Anzeige
Mehr »
Mittwoch, 06.08.2025 - Börsentäglich über 12.000 News
US-Kupfer-Geheimtipp legt nach: Strategisches Projekt zündet Phase 2 mit KI-Bohrplanung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C5SS | ISIN: BMG889121031 | Ticker-Symbol: 0RP
Tradegate
06.08.25 | 19:23
2,120 Euro
+6,53 % +0,130
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TIZIANA LIFE SCIENCES LTD Chart 1 Jahr
5-Tage-Chart
TIZIANA LIFE SCIENCES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,9502,04022:00
GlobeNewswire (Europe)
409 Leser
Artikel bewerten:
(2)

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

NEW YORK, May 23, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced advancements in moderate Alzheimer's disease treatment, showcased in a recent feature on a national public radio station across the United States. The advancement involves the use of Tiziana's novel nasal spray, foralumab, which is designed to combat brain inflammation, marking a step forward in moderate Alzheimer's research and treatment.

In the exclusive interview, Dr. Howard Weiner shared promising results from the first patient, Joe Walsh, who received the treatment. Mr. Walsh, accompanied by his wife Karen, underwent a transformative experience at Brigham and Women's Hospital, Boston, MA, where he received a monoclonal antibody via nasal administration. Intranasal foralumab, targets immune cells in the brain to mitigate inflammation, a key contributor to Alzheimer's progression.

"I've never seen anything like this, and we've tried a lot of things. So I think this is something special," stated Dr. Howard Weiner. "The reduction in brain inflammation observed in Joe Walsh represents a significant step forward in our understanding and treatment of Alzheimer's disease. We are witnessing remarkable progress with foralumab."

Karen Walsh, Joe's wife and steadfast supporter, recounted their journey from diagnosis to participation in the clinical trial. "It's been a rollercoaster," she shared. "Since Joe started the treatment, we've noticed him becoming more engaged and enjoying social activities again."

The full interview can be accessed here: https://www.tizianalifesciences.com/interview-aired-nationwide-highlighting-intranasal-foralumab-treating-moderate-alzheimers-disease/

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Tiziana's Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120


© 2025 GlobeNewswire (Europe)
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.